The present study provides a basis for the use of CORM-2 as an effective strategy to protect against sepsis-induced AKI, and exogenous CO as released by CORM-2 treatment decreases the oxidative stress and NLRP3 inflammasome activation. The gene discussed is NLRP3; the disease is Sepsis.